-transparent.png){kind=logo}
Following iv injection, melphalan was eliminated monophasically from rat serum (half-life = 0.87 hour) and monkey serum (half-life = 1.9 hours) and in rat bile (half-life = 2.4 hours) and monkey urine (half-life = 1.3 hours). In rat bile and monkey urine, 2% and 20% of the dose, respectively, was excreted in 12 hours as unchanged melphalan. At each time of tissue assay (0.5-4 hours after injection), rat spleen contained less melphalan than serum, liver, or kidneys. The kidneys and bile of monkeys contained more melphalan that serum, liver, or spleen. Only a small amount of radioactivity from labeled melphalan appeared in the feces of monkeys. Melphalan reached higher concentrations in implants of P388 and L1210 leukemia cells sensitive to melphalan than in cell lines resistant to this drug. Furthermore, the amounts of radioactivity bound to macromolecules of the sensitive tumors were higher.
R K Brown, and
G Duncan, and
D L Hill
January 1978,
Biochemical pharmacology,
R K Brown, and
G Duncan, and
D L Hill
January 1980,
Cancer treatment reports,
R K Brown, and
G Duncan, and
D L Hill
April 1980,
Cancer research,
R K Brown, and
G Duncan, and
D L Hill
January 1988,
Virchows Archiv. B, Cell pathology including molecular pathology,
R K Brown, and
G Duncan, and
D L Hill
January 1982,
Biochemical pharmacology,
R K Brown, and
G Duncan, and
D L Hill
October 1962,
Journal of the National Cancer Institute,
R K Brown, and
G Duncan, and
D L Hill
May 1987,
Cancer research,
R K Brown, and
G Duncan, and
D L Hill
January 2000,
Neoplasma,
R K Brown, and
G Duncan, and
D L Hill
February 1980,
Cancer letters,
R K Brown, and
G Duncan, and
D L Hill
July 1997,
Die Pharmazie,
